Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis

OBJECTIVE: Polypharmacy management of recurrent pericarditis (RP) often involves long-term therapies, often with negative effects. Slow tapering of oral therapies is often required to avoid recurrence. A post hoc analysis of the phase III trial Rilonacept inHibition of interleukin-1 Alpha and beta f...

Descripción completa

Detalles Bibliográficos
Autores principales: Brucato, Antonio, Wheeler, Alistair, Luis, Sushil Allen, Abbate, Antonio, Cremer, Paul C, Zou, Liangxing, Insalaco, Antonella, Lewinter, Martin, Lewis, Basil S, Lin, David, Nicholls, Stephen, Pancrazi, Massimo, Klein, Allan L, Imazio, Massimo, Paolini, John F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887401/
https://www.ncbi.nlm.nih.gov/pubmed/36316102
http://dx.doi.org/10.1136/heartjnl-2022-321328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887401/
https://www.ncbi.nlm.nih.gov/pubmed/36316102
http://dx.doi.org/10.1136/heartjnl-2022-321328

Ejemplares similares